Pharmaceutics articles from across Nature Portfolio

Treatments for tuberculosis have markedly improved in recent years, but lung disease caused by nontuberculous mycobacteria (NTM) is on the rise and lacks effective cures. This Review discusses promising small-molecule drug candidates and innovative clinical trial designs and highlights how lessons from tuberculosis therapeutic development can be applied to NTM disease.

Defects in platelet adhesion at sites of injury can lead to excessive bleeding. A study by Gandhi et al. investigates a new bispecific antibody as a possible therapy to prevent bleeding in patients with inherited defects in platelet adhesion.

We designed a method for fast aptamer selection by integrating biomaterials science, engineering principles and biology. Aptamer candidates dynamically interacting with immobilized targets in a three-dimensional, non-fouling and macroporous polyethylene glycol hydrogel were rapidly enriched and selected with high affinity against five protein targets.

Radiotheranostics combines disease-specific molecular imaging and radionuclide therapy. We present new and promising targets, tracers and isotopes for radiotheranostics and outline the road to clinical translation of the ¹⁷⁷Lu–LNC1004 radiopharmaceutical, which has recently been approved by the US Food and Drug Administration (FDA) for a phase I clinical trial.

Drug patents are different. To improve their quality ex ante, regulators can use predictive models.